interim data from can-003 clinical trial, page-22

Hi meg,

Your question relates to pursuing a secondary outcome, with using Cvac as an adjunct therapy to chemotherapy.

I believe they are doing this already with can-003 where patients in the osc group who progress are offered Cvac treatment also (someone correct me if I wrong)

This muddles OS a bit as you don't get a true indication of OS related to the drug alone. But I guess it let's you compare the benefit of administering te drug during remission rather than after progression.

With regards to canvas, it is really up to them. The biggest issue is cost. They aren't fully funded, so guaranteeing that many people to receive full courses is a lot of money. I don't think that will be possible. It's probably one to ask the team